Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: Prevalence, clinical and laboratory associations

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Gravani, Fotini ^a,b   Papadaki, Ioanna ^a   Antypa, Eleni ^a   Nezos, Andrianos ^b   Masselou, Kyriaki ^a   Ioakeimidis, Dimitrios ^a   Koutsilieris, Michael ^b   Moutsopoulos, Haralampos M ^b   Mavragani, Clio P ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DICKKOPF 1 PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SCLEROSTIN;

ADULT; AGE; ARTERIAL WALL THICKENING; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BONE DENSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PROSPECTIVE STUDY; SJOEGREN SYNDROME; URINE PH; WNT SIGNALING PATHWAY; AGED; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BONE DISEASES, METABOLIC; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; COMORBIDITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; INTIMA; MIDDLE AGED; NONPARAMETRIC TEST; ODDS RATIO; PATHOLOGY; PHYSIOLOGY; PREVALENCE; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

ADULT; AGED; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BONE DENSITY; BONE DISEASES, METABOLIC; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; STATISTICS, NONPARAMETRIC; TUNICA INTIMA;

EID: 84928613082     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0613-6     Document Type: Article

References (54)

1. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104:1887-93.
2. Toloza SM, Uribe AG, McGwin Jr G, Alarcon GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004;50:3947-57.
3. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112:3337-47.
4. Giles JT, Post WS, Blumenthal RS, Polak J, Petri M, Gelber AC, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2011;63:3216-25.
5. Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2009;48:1309-13.
6. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121:S3-8.
7. Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum. 2012;41:669-75.
8. den Uyl D, Nurmohamed MT, van Tuyl LH, Raterman HG, Lems WF. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011;13:R5.
9. Zhu TY, Griffith JF, Au SK, Tang XL, Kwok AW, Leung PC, et al. Bone mineral density change in systemic lupus erythematosus: a 5-year followup study. J Rheumatol. 2014;41:1990-7.
10. Lodder MC, Haugeberg G, Lems WF, Uhlig T, Orstavik RE, Kostense PJ, et al. Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum. 2003;49:209-15.
11. Avouac J, Koumakis E, Toth E, Meunier M, Maury E, Kahan A, et al. Increased risk of osteoporosis and fracture in women with systemic sclerosis: a comparative study with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:1871-8.
12. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev. 2010;9:A305-310.
13. Yao Q, Altman RD, Wang X. Systemic lupus erythematosus with Sjogren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. J Clin Rheumatol. 2012;18:28-32.
14. Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013;56:42-7.
15. Towler DA, Shao JS, Cheng SL, Pingsterhaus JM, Loewy AP. Osteogenic regulation of vascular calcification. Ann NY Acad Sci. 2006;1068:327-33.
16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-8.
17. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69:1103-9.
18. Vaudo G, Schillaci G, Evangelista F, Pasqualini L, Verdecchia P, Mannarino E. Arterial wall thickening at different sites and its association with left ventricular hypertrophy in newly diagnosed essential hypertension. Am J Hypertens. 2000;13:324-31.
19. Vaudo G, Bocci EB, Shoenfeld Y, Schillaci G, Wu R, Del Papa N, et al. Precocious intima-media thickening in patients with primary Sjogren's syndrome. Arthritis Rheum. 2005;52:3890-7.
20. Stergiou GS, Salgami EV. New European, American and International guidelines for hypertension management: agreement and disagreement. Expert Rev Cardiovasc Ther. 2004;2:359-68.
21. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21:1011-53
22. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399-428.
23. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129.
24. Tanko LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005;20:1912-20.
25. Hyder JA, Allison MA, Wong N, Papa A, Lang TF, Sirlin C, et al. Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am J Epidemiol. 2009;169:186-94.
26. Full LE, Ruisanchez C, Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2009;11:217.
27. Sen M, Ghosh G. Transcriptional outcome of Wnt-Frizzled signal transduction in inflammation: evolving concepts. J Immunol. 2008;181:4441-5.
28. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of vitamin D in atherosclerosis. Circulation. 2013;128:2517-31.
29. Perez-De-Lis M, Akasbi M, Siso A, Diez-Cascon P, Brito-Zeron P, Diaz-Lagares C, et al. Cardiovascular risk factors in primary Sjogren's syndrome: a case-control study in 624 patients. Lupus. 2010;19:941-8.
30. Juarez M, Toms TE, de Pablo P, Mitchell S, Bowman S, Nightingale P, et al. Cardiovascular risk factors in women with primary Sjogren's syndrome: United Kingdom primary Sjogren's syndrome registry results. Arthritis Care Res. 2014;66:757-64.
31. Cruz W, Fialho S, Morato E, Castro G, Zimmermann A, Ribeiro G, et al. Is there a link between inflammation and abnormal lipoprotein profile in Sjogren's syndrome? Joint Bone Spine. 2010;77:229-31.
32. Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F, et al. Cardiovascular disease risk burden in primary Sjogren's syndrome: results of a population-based multicentre cohort study. J Int Med. 2015. doi:10.1111/joim.12346.
33. Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Serum lipid levels in Sjogren's syndrome. Rheumatology (Oxford). 2006;45:481-4.
34. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399-406.
35. Im CH, Kim NR, Kang JW, Kim JH, Kang JY, Bae GB, et al. Inflammatory burden interacts with conventional cardiovascular risk factors for carotid plaque formation in rheumatoid arthritis. Rheumatology (Oxford, England). pii: keu376. Pubmed Epub 2014 Oct 9.
36. Dave AJ, Fiorentino D, Lingala B, Krishnan E, Chung L. Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:323-7.
37. Rachapalli SM, Kiely PD, Bourke BE. Prevalence of abnormal ankle brachial index in patients with primary Sjogren's syndrome. Clin Rheumatol. 2009;28:587-90.
38. Gerli R, Vaudo G, Bocci EB, Schillaci G, Alunno A, Luccioli F, et al. Functional impairment of the arterial wall in primary Sjogren's syndrome: combined action of immunologic and inflammatory factors. Arthritis Care Res (Hoboken). 2010;62:712-18.
39. Atzeni F, Sarzi-Puttini P, Signorello MC, Gianturco L, Stella D, Boccassini L, et al. New parameters for identifying subclinical atherosclerosis in patients with primary Sjogren's syndrome: a pilot study. Clin Exp Rheumatol. 2014;32:361-8.
40. Kaplan MJ, Salmon JE. How does interferon-alpha insult the vasculature? Let me count the ways. Arthritis Rheum. 2011;63:334-6.
41. Oryoji K, Kiyohara C, Horiuchi T, Tsukamoto H, Niiro H, Shimoda T, et al. Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A. Mod Rheumatol. 2014;24:86-92.
42. del Rincon I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014;66:264-72.
43. Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux C. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int. 2012;23:581-7.
44. Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjogren's syndrome: Autoimmune epithelitis. J Autoimmun. 2012;39:34-42.
45. Goules A, Masouridi S, Tzioufas AG, Ioannidis JP, Skopouli FN, Moutsopoulos HM. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore). 2000;79:241-9.
46. Moutsopoulos HM, Cledes J, Skopouli FN, Elisaf M, Youinou P. Nephrocalcinosis in Sjogren's syndrome: a late sequela of renal tubular acidosis. J Intern Med. 1991;230:187-91.
47. Jung SM, Kim KW, Yang CW, Park SH, Ju JH. Cytokine-mediated bone destruction in rheumatoid arthritis. Int J Immunol Res. 2014;2014:263625.
48. Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford). 2014;53:1759-66.
49. Zhou R, Zhou H, Cui M, Chen L, Xu J. The association between aortic calcification and fracture risk in postmenopausal women in China: the prospective Chongqing osteoporosis study. PLoS One. 2014;9, e93882.
50. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004;89:4246-53.
51. Claes KJ, Viaene L, Heye S, Meijers B, d'Haese P, Evenepoel P. Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013;98:3221-8.
52. Register TC, Hruska KA, Divers J, Bowden DW, Palmer ND, Carr JJ, et al. Plasma Dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in African-Americans with type 2 diabetes. J Clin Endocrinol Metab. 2013;98:E60-5.
53. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276-87.
54. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473-80.